Related Experiment Video
Updated: Aug 1, 2025

A Bedside, Single Burr Hole Approach to Multimodality Monitoring in Severe Brain Injury
Published on: March 26, 2019
Current and emerging diagnostic and management approaches for idiopathic intracranial hypertension
Ravi Piccus1, Mark Thaller2,3,4, Alexandra J Sinclair2,3,4
1Medical school, University of Birmingham, Birmingham, UK.
Insights
Idiopathic intracranial hypertension (IIH) is increasingly linked to obesity and metabolic dysfunction. Emerging evidence suggests IIH is a systemic metabolic disease, necessitating broader treatment approaches beyond eye-focused management.
Area of Science:
- Neurology
- Metabolic Disorders
- Ophthalmology
Background:
- Idiopathic intracranial hypertension (IIH) presents with elevated intracranial pressure, causing severe headaches and potential vision loss.
- The condition's incidence and prevalence correlate with obesity rates, yet no approved treatments exist.
- Current management primarily targets papilledema, overlooking potential systemic aspects.
Approach:
- This review explores emerging pathophysiological evidence for IIH.
- It outlines diagnostic pathways and discusses current and potential therapeutic strategies.
- The focus is on novel targeted therapeutics for IIH.
Key Points:
- IIH exhibits metabolic dysregulation and systemic manifestations beyond obesity.
- Future management must address debilitating headaches and associated systemic risks.
- Systemic risks include preeclampsia, gestational diabetes, and major cardiovascular events.
Conclusions:
- IIH is increasingly recognized as a systemic metabolic disease.
- Management strategies need to evolve beyond ocular-centric approaches.
- Targeted therapeutics addressing metabolic pathways are on the horizon.
Introduction:
Idiopathic intracranial hypertension is characterized by raised intracranial pressure that triggers disabling headaches and can cause permanent visual loss. There is an increased incidence and prevalence of the condition linked to location-specific obesity rates. There are no licensed treatments for the condition. The majority of approaches to managing the disease prioritize resolution of papilledema. However, evidence is emerging that idiopathic intracranial hypertension is a systemic metabolic disease.
Areas Covered:
The aim of this review is to present the emerging pathophysiology evidence which is leading to novel targeted therapeutics. The diagnostic pathway is outlined. The current and potential management approaches for idiopathic intracranial hypertension are also discussed.
Expert Opinion:
Idiopathic intracranial hypertension is a condition with metabolic dysregulation with systemic manifestations that are present over and above what can be expl.ained by obesity alone. While most of the current management of this condition focuses on the eyes, future management needs to address the disabling headaches and the systemic risks of preeclampsia, gestational diabetes, and major cardiovascular events.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management

